Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* Patients must have the below proven, probable or possible deep mycosis;~  1. invasive aspergillosis~ 2. chronic pulmonary aspergillosis~ 3. mucormycosis~ 4. cryptococcosis~* Female patients must be non-lactating and at no risk for pregnancy.~Main Exclusion Criteria:~* Women who are pregnant or breastfeeding.~* Patients with hypersensitivity to any of the components of the azole class of antifungals or the investigational product.~* Patients at high risk for QT/QTc prolongation, or patients with risk factors for torsades de pointes, or taking concomitant medications known to prolong the QT/QTc interval.~* Patients with a history of short QT syndrome.~* Patients with liver dysfunction at enrollment.~* Patients with moderate to severe kidney dysfunction at enrollment.~* Patients who receive prohibited concomitant drugs.~* Patients with any other fungal infection other than Aspergillus species, order Mucorales, or Cryptococcus species.~* Patients who are not expected to survive study duration.~* Patients with an underlying disease, complication or general condition that would complicate safety and efficacy evaluations.~* Patients with a history of taking voriconazole for deep mycosis and showing no response to this treatment.~* Patients taking systemic antifungals who are unable to stop taking these drugs during the study, or who are showing signs of improvement in their symptoms of deep mycosis as a result of these drugs.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AK1820 (Type: EXPERIMENTAL): Participants will receive a loading dose of isavuconazole, 200 mg three times a day by intravenous infusion (IV) or orally for the first 2 days followed by a maintenance dose from Day 3 of 200 mg once daily either IV or orally until they will reach a treatment endpoint or for a maximum of 84 days.
- Voriconazole (Type: ACTIVE_COMPARATOR): Participants will receive a loading dose of voriconazole, 6 mg/kg every 12 hours IV or 300 mg every 12 hours orally for the first 24 hours, followed by a maintenance dose from Day 2 of 4 mg/kg every 12 hours by IV or 200 mg every 12 hours orally, until they will reach a treatment endpoint or for a maximum of 84 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).